The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies. Compare side effects here.

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Treatment with cenobamate may reduce seizure frequency among patients with drug-resistant epilepsy after 3 months.